Antonio Di Zazzo1, Maryam Tahvildari, George J Florakis, Reza Dana. 1. *Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Department of Ophthalmology, Harvard Medical School, Boston, MA; and†Columbia University, Edward S. Harkness Eye Institute, New York, NY.
Abstract
PURPOSE: To report the ocular manifestations of phospholipase-Cγ2-associated antibody deficiency and immune dysregulation (PLAID). METHODS: Case report and literature review. RESULTS: A 21-year-old woman diagnosed with PLAID was referred for evaluation of repeated episodes of ocular inflammation resulting in bilateral peripheral corneal pannus with episcleritis and corneal scarring accompanied by systemic manifestations including epidermolysis bullosa and interstitial lung disease. Systemic immunosuppression with corticosteroids and interleukin-1 (IL-1) receptor antagonist (anakinra) was supplemented with topical anakinra to avoid systemic side effects, which resulted in partial improvement of the ocular symptoms. Oral prednisone was restarted to treat active lesions during bouts of inflammation. CONCLUSIONS: Ocular PLAID is a bilateral chronic or recurrent inflammatory disease of the ocular surface leading to severe and early cicatricial ocular surface and corneal involvement because of high IL-1 production. Management of PLAID may require both topical and systemic immunomodulatory treatments, potentially including targeted local anti-IL-1 therapy.
PURPOSE: To report the ocular manifestations of phospholipase-Cγ2-associated antibody deficiency and immune dysregulation (PLAID). METHODS: Case report and literature review. RESULTS: A 21-year-old woman diagnosed with PLAID was referred for evaluation of repeated episodes of ocular inflammation resulting in bilateral peripheral corneal pannus with episcleritis and corneal scarring accompanied by systemic manifestations including epidermolysis bullosa and interstitial lung disease. Systemic immunosuppression with corticosteroids and interleukin-1 (IL-1) receptor antagonist (anakinra) was supplemented with topical anakinra to avoid systemic side effects, which resulted in partial improvement of the ocular symptoms. Oral prednisone was restarted to treat active lesions during bouts of inflammation. CONCLUSIONS: Ocular PLAID is a bilateral chronic or recurrent inflammatory disease of the ocular surface leading to severe and early cicatricial ocular surface and corneal involvement because of high IL-1 production. Management of PLAID may require both topical and systemic immunomodulatory treatments, potentially including targeted local anti-IL-1 therapy.
Authors: Ilpo S J Tuominen; Yrjö T Konttinen; Minna H Vesaluoma; Jukka A O Moilanen; Maaret Helintö; Timo M T Tervo Journal: Invest Ophthalmol Vis Sci Date: 2003-06 Impact factor: 4.799
Authors: Michael J Ombrello; Elaine F Remmers; Guangping Sun; Alexandra F Freeman; Shrimati Datta; Parizad Torabi-Parizi; Naeha Subramanian; Tom D Bunney; Rhona W Baxendale; Marta S Martins; Neil Romberg; Hirsh Komarow; Ivona Aksentijevich; Hun Sik Kim; Jason Ho; Glenn Cruse; Mi-Yeon Jung; Alasdair M Gilfillan; Dean D Metcalfe; Celeste Nelson; Michelle O'Brien; Laura Wisch; Kelly Stone; Daniel C Douek; Chhavi Gandhi; Alan A Wanderer; Hane Lee; Stanley F Nelson; Kevin V Shianna; Elizabeth T Cirulli; David B Goldstein; Eric O Long; Susan Moir; Eric Meffre; Steven M Holland; Daniel L Kastner; Matilda Katan; Hal M Hoffman; Joshua D Milner Journal: N Engl J Med Date: 2012-01-11 Impact factor: 91.245
Authors: Francisco Amparo; Mohammad H Dastjerdi; Andre Okanobo; Giulio Ferrari; Leila Smaga; Pedram Hamrah; Ula Jurkunas; Debra A Schaumberg; Reza Dana Journal: JAMA Ophthalmol Date: 2013-06 Impact factor: 7.389
Authors: Qing Zhou; Geun-Shik Lee; Jillian Brady; Shrimati Datta; Matilda Katan; Afzal Sheikh; Marta S Martins; Tom D Bunney; Brian H Santich; Susan Moir; Douglas B Kuhns; Debra A Long Priel; Amanda Ombrello; Deborah Stone; Michael J Ombrello; Javed Khan; Joshua D Milner; Daniel L Kastner; Ivona Aksentijevich Journal: Am J Hum Genet Date: 2012-09-20 Impact factor: 11.025
Authors: Andrea Martín-Nalda; Claudia Fortuny; Lourdes Rey; Tom D Bunney; Laia Alsina; Ana Esteve-Solé; Daniel Bull; Maria Carmen Anton; María Basagaña; Ferran Casals; Angela Deyá; Marina García-Prat; Ramon Gimeno; Manel Juan; Helios Martinez-Banaclocha; Juan J Martinez-Garcia; Anna Mensa-Vilaró; Raquel Rabionet; Nieves Martin-Begue; Francesc Rudilla; Jordi Yagüe; Xavier Estivill; Vicente García-Patos; Ramon M Pujol; Pere Soler-Palacín; Matilda Katan; Pablo Pelegrín; Roger Colobran; Asun Vicente; Juan I Arostegui Journal: J Clin Immunol Date: 2020-07-15 Impact factor: 8.317